IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Claims Against Esperion Therapeutics, Inc. & Strong...
January 06 2016 - 10:03PM
Business Wire
Khang & Khang LLP announces that it is investigating claims
of potential misrepresentations by Esperion Therapeutics, Inc.
(“Esperion” or the “Company”) (NASDAQ: ESPR). The investigation
focuses on whether the Company and its officers violated securities
laws by issuing misleading information to investors.
If you purchased shares of Esperion during the Class Period,
please contact Joon M. Khang, Esquire, of Khang & Khang, 18101
Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone:
949-419-3834, or by e-mail at joon@khanglaw.com.
There has been no class certification in this case. Until
certification occurs, you are not represented by an attorney. You
may choose to take no action and remain a passive class member.
The investigation concerns whether the Company violated Sections
10(b) and 20(a) of the Securities Exchange Act of 1934.
Specifically, the investigation will focus on whether the Company’s
efforts to receive regulatory approval for its developmental
cholesterol drug, ETC-1002, was in accordance with the law.
If you wish to learn more about this lawsuit, or if
you have any questions concerning this notice or your rights,
please contact Joon M. Khang, a prominent litigator for almost two
decades, by telephone: 949-419-3834, or by e-mail at
joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160106006793/en/
KHANG & KHANG LLPJoon M. Khang, Esq.Telephone:
949-419-3834Facsimile: 949-225-4474joon@khanglaw.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024